Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.50 |
| ▸ | CDK4 | P11802 | 6/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7978098 | 0.90 | CDK2 (0.57) | CDK2CDK4CCNE1AURKAMAPK13 | |
| SCHEMBL10285690 | 0.90 | CDK2 (0.46) | CDK2CDK4CCNE1MEN1KMT2A | |
| SCHEMBL700061 | 0.88 | CAMK2D (0.54) | CDK2CDK4CCNE1MAPK13MAPK12 | |
| SCHEMBL10251999 | 0.86 | ABL1 (0.48) | CDK2CDK4CCNE1AURKAKDM4E | |
| SCHEMBL7978525 | 0.84 | CDK2 (0.73) | CDK2CDK4CCNE1AURKAKDM4E | |
| SCHEMBL6245628 | 0.84 | CDK2 (0.69) | CDK2CDK4CCNE1ABL1MAPK13 | |
| SCHEMBL699840 | 0.82 | HDAC1 (0.63) | CDK2CDK4CCNE1ABL1MAPK13 | |
| SCHEMBL6243791 | 0.80 | CDK2 (0.57) | CDK2CDK4CCNE1GSK3BCDK1 | |
| SCHEMBL7975457 | 0.80 | CDK2 (0.55) | CDK2CDK4CCNE1AURKAKDM4E | |
| SCHEMBL7964916 | 0.78 | CDK2 (0.51) | CDK2CDK4CCNE1AURKAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124764-B2 | Fused heterocyclyc inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010009155-A2 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029638-A1 | FUSED HETEROCYCLYC INHIBITOR COMPOUNDS | HDAC1, HDAC11, HDAC7 | CDK2 16/4885CDK4 15/4885CCNE1 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.